FitLife Brands (FTLF) Competitors

Organogenesis (NASDAQ:ORGO) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Does the media favor ORGO or FTLF?

In the previous week, FitLife Brands had 5 more articles in the media than Organogenesis. MarketBeat recorded 5 mentions for FitLife Brands and 0 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.76 beat FitLife Brands' score of 0.51 indicating that Organogenesis is being referred to more favorably in the media.

Company	Overall Sentiment
Organogenesis	Very Positive
FitLife Brands	Positive

Which has preferable valuation and earnings, ORGO or FTLF?

FitLife Brands has lower revenue, but higher earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$482.04M	1.29	$860K	-$0.14	-34.93
FitLife Brands	$64.47M	2.48	$8.98M	$0.84	20.24

Is ORGO or FTLF more profitable?

FitLife Brands has a net margin of 12.63% compared to Organogenesis' net margin of -1.92%. FitLife Brands' return on equity of 21.70% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-1.92%	-0.37%	-0.20%
FitLife Brands	12.63%	21.70%	13.45%

Which has more volatility and risk, ORGO or FTLF?

Organogenesis has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, FitLife Brands has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Do insiders and institutionals believe in ORGO or FTLF?

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by insiders. Comparatively, 61.4% of FitLife Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Do analysts prefer ORGO or FTLF?

Organogenesis currently has a consensus target price of $7.50, indicating a potential upside of 53.37%. FitLife Brands has a consensus target price of $22.00, indicating a potential upside of 29.41%. Given Organogenesis' higher possible upside, equities research analysts clearly believe Organogenesis is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
FitLife Brands	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

FitLife Brands beats Organogenesis on 11 of the 16 factors compared between the two stocks.